Growth-hormone secretagogues & GH-axis peptides
Octreotide
Also known as Sandostatin · somatostatin analogue
A long-acting synthetic analogue of somatostatin — the hormone that switches growth-hormone release off.
In 60 seconds
Approved for acromegaly and neuroendocrine tumours, with injectable, depot and oral forms; also used in chylothorax and other off-label settings. Gallstones and gastrointestinal effects are the class-recognised adverse effects; glucose regulation can shift.
- Reviews octreotide’s chemistry, pharmacology, clinical uses and adverse effects.
- A phase 3 trial evaluated a subcutaneous octreotide depot in acromegaly.
- Reviews oral octreotide as a somatostatin-receptor ligand for acromegaly.
Mechanism
Octreotide binds somatostatin receptors (mainly SSTR2), suppressing GH, IGF-1 and many gut hormones. It is the pharmacological opposite of GH secretagogues and a standard treatment for GH excess.
Research status
Approved for acromegaly and neuroendocrine tumours, with injectable, depot and oral forms; also used in chylothorax and other off-label settings.
Key studies
Reviews octreotide’s chemistry, pharmacology, clinical uses and adverse effects.
Octreotide, a new somatostatin analogue — Clin Pharm, 1989 · PMID 2653711
A phase 3 trial evaluated a subcutaneous octreotide depot in acromegaly.
Octreotide Subcutaneous Depot for Acromegaly: A Randomized, Double-blind, Placebo-controlled Phase 3 Trial, ACROINNOVA 1 — J Clin Endocrinol Metab, 2025 · PMID 39378125
Reviews oral octreotide as a somatostatin-receptor ligand for acromegaly.
Treatment of acromegaly with oral octreotide — Best Pract Res Clin Endocrinol Metab, 2024 · PMID 38443224
Reviews octreotide and octreotide-based targeted delivery systems.
Octreotide and Octreotide-derived delivery systems — J Drug Target, 2023 · PMID 37211679
Safety signals in the literature
Gallstones and gastrointestinal effects are the class-recognised adverse effects; glucose regulation can shift.
Legal status (South Africa)
Not a registered medicine for human use in South Africa unless SAHPRA-registered under its own name; growth-hormone secretagogues are prohibited in sport under the WADA list. Supplied, where we stock it, strictly for laboratory research.
Not stocked yet — get notified
Tell us you want Octreotide and we’ll email you if we add it. Requests decide what we source next.
Not stocked yet
Get notified when we add Octreotide
One email, only when it reaches the catalogue. Every request is counted when we choose what to stock next.
Comparisons
Questions
What is Octreotide?
A long-acting synthetic analogue of somatostatin — the hormone that switches growth-hormone release off. Octreotide binds somatostatin receptors (mainly SSTR2), suppressing GH, IGF-1 and many gut hormones. It is the pharmacological opposite of GH secretagogues and a standard treatment for GH excess.
What is the research status of Octreotide?
Approved for acromegaly and neuroendocrine tumours, with injectable, depot and oral forms; also used in chylothorax and other off-label settings.
What safety signals are reported for Octreotide?
Gallstones and gastrointestinal effects are the class-recognised adverse effects; glucose regulation can shift.
Does Living Water Labs stock Octreotide?
Not at present. Octreotide is profiled here for reference, with citations to the published literature. You can ask to be notified if we add it. Not a registered medicine for human use in South Africa unless SAHPRA-registered under its own name; growth-hormone secretagogues are prohibited in sport under the WADA list. Supplied, where we stock it, strictly for laboratory research.
More in GH secretagogues
Research reference only. This page summarises published literature; it is not medical advice and contains no guidance on human use. Products supplied by Living Water Labs are for laboratory research only.
